Compare Adaptive Biotechnologies Corp (ADPT) vs Waste Management, Inc. (WM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Waste Management, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $19.9 (market cap $3.33B), while Waste Management, Inc. trades at $235.97 (market cap $95.26B). The key difference: Waste Management, Inc. is far larger — about 28.6× Adaptive Biotechnologies Corp's market cap, and Waste Management, Inc. pays a 1.49% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | WM | |
|---|---|---|
Market Cap | $3.33B | $95.26B |
Sector | Health | Industrials |
52-Week High | $22.37 | $246.51 |
52-Week Low | $10.24 | $196.77 |
Enterprise Value | $3.19B | $117.99B |
Dividend Yield | — | 1.49% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
WM trades at $237.21, up 2.96% today and near its 52-week high of $248.13. The stock shows bullish technical signals with strong moving averages and positive momentum indicators. Fundamentally, revenue grew to $25.20B in 2025 with a net income margin of 10.99%, though recent quarters saw mixed earnings results. Analyst consensus is bullish with a $261 price target, and the company maintains a solid dividend with recent payout of $0.95 per share.
Outlook remains positive driven by pricing discipline and renewable energy initiatives, but risks include elevated valuation multiples and debt levels. The stock offers stability through economic cycles but faces execution risks in maintaining margin growth amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Waste Management, Inc.
Waste Management ranks as the largest integrated provider of traditional solid waste services in the United States, operating approximately 260 active landfills and about 340 transfer stations. The company serves residential, commercial, and industrial end markets and is also a leading recycler in North America.
Read more on WM →
